Payment overview · 2025
General Payments
$132.61
2 reported records · 2 companies
Healthcare provider profile · identity verified
Wilmer A Sanchez, M.D.
Allopathic & Osteopathic Physicians|General Practice · LAJAS, PR · NPI 1023289238
Verified facts
What the public records show
CMS Open Payments records show Wilmer A Sanchez, M.D. received $132.61 in general payments during 2025 across 2 reported records.
AstraZeneca Pharmaceuticals LP accounted for 85.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Farxiga by this doctor in 2024.
PBG PUERTO RICO LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 738 records involving 435 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $113.38 | 85.5% | 1 | 2025 |
| PBG PUERTO RICO LLC | Unresolved — no canonical attribution shown | $19.23 | 14.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $132.61 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $113.38 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PBG PUERTO RICO LLC | $19.23 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PBG PUERTO RICO LLC | $19.23 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
74 | 15 |
| PBG PUERTO RICO LLC Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 738 supporting records · 435 recipient NPIs · example record 1228798592 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 952 | 137 |
| Gabapentin | Gabapentin | 773 | 114 |
| Atorvastatin Calcium | Atorvastatin Calcium | 446 | 163 |
| Omeprazole | Omeprazole | 414 | 83 |
| Famotidine | Famotidine | 401 | 91 |
| Losartan Potassium | Losartan Potassium | 361 | 111 |
| Amlodipine Besylate | Amlodipine Besylate | 323 | 106 |
| Metformin Hcl | Metformin Hcl | 300 | 90 |
| Simvastatin | Simvastatin | 287 | 91 |
| Sertraline Hcl | Sertraline Hcl | 258 | 48 |
| Lisinopril | Lisinopril | 248 | 74 |
| Montelukast Sodium | Montelukast Sodium | 228 | 61 |
| Duloxetine Hcl | Duloxetine Hcl | 227 | 77 |
| Hydrochlorothiazide | Hydrochlorothiazide | 225 | 67 |
| Synthroid | Levothyroxine Sodium | 212 | 33 |
| Lansoprazole | Lansoprazole | 202 | 54 |
| Alendronate Sodium | Alendronate Sodium | 192 | 28 |
| Trazodone Hcl | Trazodone Hcl | 179 | 53 |
| Clonazepam | Clonazepam | 178 | 32 |
| Glimepiride | Glimepiride | 177 | 52 |
| Clopidogrel | Clopidogrel Bisulfate | 176 | 37 |
| Cilostazol | Cilostazol | 169 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 167 | 32 |
| Furosemide | Furosemide | 166 | 42 |
| Baclofen | Baclofen | 159 | 111 |
| Azithromycin | Azithromycin | 154 | 114 |
| Temazepam | Temazepam | 154 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 142 | 45 |
| Meloxicam | Meloxicam | 131 | 83 |
| Pantoprazole Sodium | Pantoprazole Sodium | 128 | 32 |
| Quetiapine Fumarate | Quetiapine Fumarate | 119 | 15 |
| Carvedilol | Carvedilol | 107 | 31 |
| Donepezil Hcl | Donepezil Hcl | 106 | 24 |
| Pregabalin | Pregabalin | 104 | 39 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 90 | 46 |
| Alprazolam | Alprazolam | 89 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 89 | 17 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 78 | 65 |
| Farxiga | Dapagliflozin Propanediol | 74 | 15 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 74 | 15 |
| Glipizide | Glipizide | 73 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 71 | 22 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 70 | 23 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 67 | 24 |
| Meclizine Hcl | Meclizine Hcl | 67 | 28 |
| Pioglitazone Hcl | Pioglitazone Hcl | 66 | 18 |
| Dexamethasone | Dexamethasone | 60 | 50 |
| Ezetimibe | Ezetimibe | 60 | 19 |
| Levofloxacin | Levofloxacin | 58 | 55 |
| Allopurinol | Allopurinol | 54 | 11 |
| Finasteride | Finasteride | 54 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 54 | 12 |
| Buspirone Hcl | Buspirone Hcl | 53 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 53 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 50 | 17 |
| Prednisone | Prednisone | 49 | 21 |
| Irbesartan | Irbesartan | 48 | 15 |
| Lorazepam | Lorazepam | 47 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 46 | 38 |
| Latanoprost | Latanoprost | 45 | 11 |
| Warfarin Sodium | Warfarin Sodium | 45 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 42 | suppressed |
| Humalog | Insulin Lispro | 40 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 40 | suppressed |
| Xarelto | Rivaroxaban | 40 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 39 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 38 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 38 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 38 | 22 |
| Doxazosin Mesylate | Doxazosin Mesylate | 37 | 12 |
| Mirtazapine | Mirtazapine | 35 | suppressed |
| Memantine Hcl | Memantine Hcl | 34 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 33 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 32 | suppressed |
| Januvia | Sitagliptin Phosphate | 32 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 19 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 30 | suppressed |
| Sure Comfort | Syringe And Needle,insulin,1ml | 30 | suppressed |
| Atenolol | Atenolol | 29 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 29 | 18 |
| Brilinta | Ticagrelor | 28 | suppressed |
| Levetiracetam | Levetiracetam | 28 | suppressed |
| Mupirocin | Mupirocin | 28 | 24 |
| Enalapril Maleate | Enalapril Maleate | 27 | suppressed |
| Methotrexate | Methotrexate Sodium | 27 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 27 | suppressed |
| Sucralfate | Sucralfate | 27 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 27 | 17 |
| Humulin N | Insulin Nph Human Isophane | 26 | suppressed |
| Methimazole | Methimazole | 26 | suppressed |
| Nitroglycerin | Nitroglycerin | 26 | 14 |
| Verapamil Er | Verapamil Hcl | 26 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 22 |
| Divalproex Sodium Er | Divalproex Sodium | 24 | suppressed |
| Pentoxifylline | Pentoxifylline | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 22 |
| Naproxen | Naproxen | 23 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | 14 |
| Nabumetone | Nabumetone | 22 | 11 |
| Risperidone | Risperidone | 22 | suppressed |
| Sulindac | Sulindac | 22 | 16 |
| Ofloxacin | Ofloxacin | 21 | 19 |
| Carbamazepine | Carbamazepine | 20 | suppressed |
| Indomethacin | Indomethacin | 20 | 12 |
| Sure Comfort | Syringe-Needle,insulin,0.5 Ml | 20 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 19 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 19 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 18 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Cephalexin | Cephalexin | 18 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 18 | 15 |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | 16 |
| Mesalamine | Mesalamine | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 16 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Eliquis | Apixaban | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 16 | suppressed |
| Humulin R | Insulin Regular, Human | 16 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 16 | suppressed |
| Ssd | Silver Sulfadiazine | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Calcitriol | Calcitriol | 15 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 15 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 15 | 14 |
| Methylprednisolone | Methylprednisolone | 14 | 12 |
| Spironolactone | Spironolactone | 14 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 14 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Mupirocin | Mupirocin Calcium | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Timolol Maleate | Timolol Maleate | 13 | suppressed |
| Acarbose | Acarbose | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $132.61 · 2 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, NURTEC ODT, ZAVZPRET | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error